Spots Global Cancer Trial Database for A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Official Title: An Open-label, Multicenter Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab (if Given as Part of Local Standard Practice) in Patient With Metastatic Colorectal Adenocarcinoma
Study ID: NCT00478634
Interventions
Study Description
Brief Summary: This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Highlands Oncology Group, Fayetteville, Arkansas, United States
Comprehensive nBlood and Cancer Care, Bakersfield, California, United States
UCSD - Moores Cancer Center, La Jolla, California, United States
Comprehensive Cancer Care, Los Angeles, California, United States
North Valley Hematology/Oncology Medical Group: The Thomas & Dorothy Leavey Cancer Center, Northridge, California, United States
Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States
Norwalk Hospital, Norwalk, Connecticut, United States
Gerogetown University Lombardi Cancer Center, Washington, District of Columbia, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Oncology Specialists, Park Ridge, Illinois, United States
Nevada Cancer Institute, Las Vegas, Nevada, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Richmond University Medical Center, Staten Island, New York, United States
UNC School of Medicine, Chapel Hill, North Carolina, United States
Oncology/Hematology Associates, Bethlehem, Pennsylvania, United States
Arlington Cancer Center, Arlington, Texas, United States
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
